Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Axsome Thera (NQ: AXSM ) 93.35 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Axsome Thera < Previous 1 2 3 4 5 6 7 8 9 ... 19 20 Next > 3 Bargain Stocks to Buy in a Market That's Priced for Perfection Today 7:30 EDT Yes, bargains can still be found in the stock market. Via The Motley Fool Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 October 15, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views October 04, 2024 Via Benzinga 1 Under-the-Radar Biotech Stock to Buy and Hold September 29, 2024 It could be an industry giant in the making. Via The Motley Fool Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 September 24, 2024 Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders From Axsome Therapeutics, Inc. Via GlobeNewswire What Analysts Are Saying About Axsome Therapeutics Stock September 09, 2024 Via Benzinga Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine September 04, 2024 FDA sets PDUFA action goal date of January 31, 2025 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Participate in Investor Conferences in September August 27, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Unveiling 14 Analyst Insights On Axsome Therapeutics August 22, 2024 Via Benzinga Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. August 21, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts August 05, 2024 Via Benzinga Decoding 9 Analyst Evaluations For Axsome Therapeutics July 18, 2024 Via Benzinga New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... Via PressReach Exposures Product Safety AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm August 10, 2024 From Bragar Eagel & Squire Via GlobeNewswire Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday August 06, 2024 Via Benzinga Should You Buy This Sinking Stock on the Dip? June 27, 2024 The biotech isn't having the best year. Via The Motley Fool Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript August 05, 2024 AXSM earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Why Axsome Therapeutics Stock Is Sinking Today August 05, 2024 Investors were unhappy with Axsome's worse-than-expected Q2 loss. Via The Motley Fool Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth August 05, 2024 The company makes treatments for depression and excessive daytime sleepiness. Via Investor's Business Daily Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 05, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected July 25, 2024 EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected July 25, 2024 From FN Media Group LLC Via GlobeNewswire Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible' July 24, 2024 Jim Cramer discusses Torm, Trane, Sap and Axsome Therapeutics on CNBC's "Mad Money Lightning Round." Via Benzinga 7 Biotech Stocks to Keep on Your Clinical Radar July 23, 2024 Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. Via InvestorPlace Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future July 22, 2024 Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-adjusted topline growth in five years, driven by marketed drugs Auvelity... Via Benzinga Bull Market and Beyond: 2 Stocks Just Waiting to Soar July 15, 2024 These innovative drugmakers are hard to ignore. Via The Motley Fool Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 July 11, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire The 3 Best Biotech Stocks to Buy in July 2024 July 05, 2024 For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. Via InvestorPlace 3 Undervalued Biotech Gems With 200%+ Analyst Price Targets July 04, 2024 These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. Via InvestorPlace Why Axsome Therapeutics Stock Is Sinking Today June 11, 2024 A short-seller report is causing a sell-off of the biotech stock. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 19 20 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.